CROSS

Regimen

Experimental
weekly carboplatin + paclitaxel x5 + 41.4 Gy radiotherapy followed by surgery
Control
surgery alone

Population

Resectable esophageal or EGJ cancer (75% adenocarcinoma, 23% SCC)

Key finding

mOS 49.4 vs 24.0 mo (HR 0.657, 95% CI 0.495-0.871, P=0.003); R0 92% vs 69%; pCR 29% (overall), 23% (adenoca), 49% (SCC)

Source: PMID 22646630

Timeline

    Guideline citations

    • NCCN GASTRIC (p.24)
    • CSCO GASTRIC 2025 (p.68)⚠️ OCR source